Summary: Using titanate nanowires treated with cerebrolysin, researchers have been able to target delivery to the brain and through the central nervous system. Researchers report the use of nanowires to deliver drugs could be beneficial in the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases.
Source: University of Arkansas.
Millions of Americans suffer from neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Researchers have identified promising new treatments, such as cerebrolysin, but current clinical approaches are ineffective because critical concentrations of the drug dissipate within the body before reaching the blood-brain barrier and central nervous system.
To address this problem, researchers have focused on various delivery vehicles for sustained and targeted drug release. An effective, targeted approach would eliminate the need for inefficient, high dosages that cause adverse side effects.
In recent years, biomedical engineers have experimented with nanomaterials as an approach to targeted delivery. Under the direction of Ryan Tian, associate professor of chemistry at the University of Arkansas, doctoral student Asya Ozkizilcik has improved the nanowiring of drugs for an international team of researchers who are working on a new method for treating neurodegenerative diseases.
Ozkizilcik worked with titanate, a bioceramic material made of titanium dioxide. Titanate has many advantages. Its nanowires are chemically inert and therefore do not interact with biological components. In addition to biocompatibility, the nanowires are resistant to corrosion in biological fluids, which is ideal for sustained, in vivo drug release without harming cells or tissues.
Ozkizilcik made the titanate nanowires in an autoclave treatment and then loaded cerebrolysin onto the nanowires. Though detailed mechanisms are unclear, the nanoparticles may prolong the intact delivery of cerebrolysin all the way to blood-brain barrier, where high concentrations of the drug are then released into the brain. The drug’s efficacy was tested on rat models with co-administration of mesenchymal stem cells. Mesenchymal stem cells have been used for developing therapeutics for various autoimmune and other diseases.
Ozkizilcik’s research is part of the international team’s broader goal of finding a more effective treatment for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The international team has also demonstrated efficacy of this treatment on a Parkinson’s disease model after traumatic brain injury.
“We believe titanate nanowires could be considered as potential drug delivery tools for neurodegenerative diseases and may be translated into clinical use in future,” Ozkizilcik said.
About this neuroscience research article
Funding: The studies were funded by the Engineering and Physical Sciences Research Council (EPSRC).
Source: Matt McGowan – University of Arkansas Publisher: Organized by NeuroscienceNews.com. Image Source: NeuroscienceNews.com image is in the public domain. Original Research: The findings were presented at Neuroscience 2017.
Cite This NeuroscienceNews.com Article
[cbtabs][cbtab title=”MLA”]University of Arkansas “Nanowired Drugs Could Treat Alzheimer’s and Parkinson’s Patients.” NeuroscienceNews. NeuroscienceNews, 16 November 2017. <https://neurosciencenews.com/nanowire-drug-neurodegeneration-7958/>.[/cbtab][cbtab title=”APA”]University of Arkansas (2017, November 16). Nanowired Drugs Could Treat Alzheimer’s and Parkinson’s Patients. NeuroscienceNews. Retrieved November 16, 2017 from https://neurosciencenews.com/nanowire-drug-neurodegeneration-7958/[/cbtab][cbtab title=”Chicago”]University of Arkansas “Nanowired Drugs Could Treat Alzheimer’s and Parkinson’s Patients.” https://neurosciencenews.com/nanowire-drug-neurodegeneration-7958/ (accessed November 16, 2017).[/cbtab][/cbtabs]